MF Researcher Database

Researchers Database

Advance

NAIKI Taku

    Graduate School of Medical Sciences Department of Nephro-urology　Associate Professor
Last Updated :2024/07/05

Researcher Information

Research funding number

  • 50551272

ORCID ID

J-Global ID

Research Interests

  • 酸化ストレス   ロボット支援下手術   泌尿器悪性腫瘍   

Research Areas

  • Life sciences / Pathobiochemistry
  • Life sciences / Urology

Academic & Professional Experience

  • 2024/04 - Today  Nagoya City University West Medical CenterDepartment of urologyAssociate Professor
  • 2018/03 - 2024/03  Nagoya City UniversityGraduate School of Medical Sciences Department of Nephro-Urology講師
  • 2016/04 - 2018/02  Nagoya City UniversityGraduate School of Medical Sciences Department of Nephro-Urology助教
  • 2003/04 - 2005/03  名古屋市立大学病院臨床研修医

Education

  • 2008/04 - 2012/03  Nagoya City University  大学院
  • 1997/04 - 2003/03  Nagoya City University

Published Papers

MISC

Awards & Honors

  • 2023/11 名古屋市立大学 理事長賞 臨床部門
  • 2023/10 Best presentation award in Asian Oncology Society 2023 annual congress
  • 2020/03 日本泌尿器科学会 JUA EAU Academic Exchange Program
  • 2015/12 前立腺財団研究助成 最優秀演題
  • 2013/04 日本泌尿器科学会総会 第7回ヤングリサーチグラント
  • 2011/03 科学技術交流財団 第5回わかしゃち奨励賞最優秀賞

Research Grants & Projects

  • 日本学術振興会：科学研究費助成事業
    Date (from‐to) : 2022/04 -2025/03 
    Author : 内木 綾; 惠谷 俊紀; 内木 拓; 高橋 智
  • 日本学術振興会：科学研究費助成事業 基盤研究(C)
    Date (from‐to) : 2021/04 -2024/03 
    Author : 内木 拓
     
    私たちは、ラットのプロバシン遺伝子プロモーターの下流に、SV40ラージT抗原の遺伝子を結合して得られるPBSVTジーンを、Sprague-Dawley (SD)系ラットの受精卵に導入し、前立腺癌動物モデル(TRAP)を確立した。またTRAPから得られた癌組織を、去勢したヌードマウス皮下に移植し長期に継代することで、アンドロゲンの枯渇した状態でも、安定して増殖するCRPCモデルを樹立した。私たちはこのCRPCモデルの解析によって、酸化ストレスの制御機構がCRPCの増殖・進展に促進的に働いていることを解明した。また抗酸化剤によって、AR-V7の発現低下を介してCRPCの増殖抑制が起こる事を解明し、さらにAR-V7を制御する新たなマイクロRNAであるmiR-8080を、世界に先駆けて発見した。そして今回、CRPC転移モデルにおいて去勢抵抗性を獲得する前後でcDNAマイクロアレイを行った結果、CRPCにおいてこれまで文献上報告のない遺伝子Cx43の発現低下を、新たに発見することができた。さらに、TCGAの癌ゲノムデータベースを用いた解析でも、ヒト前立腺組織におけるCx43タンパクの低発現は、予後不良因子となりうることを証明した。
  • 日本学術振興会：科学研究費助成事業 基盤研究(C)
    Date (from‐to) : 2020/04 -2023/03 
    Author : 惠谷 俊紀; 河合 憲康; 内木 綾; 永井 隆; 安藤 亮介; 飯田 啓太郎; 安井 孝周; 内木 拓; 野崎 哲史
     
    (1)LSD1の発現プロファイルの検討：前立腺癌患者における臨床検体を用いて、悪性度（Gleason score）ごとのLSD1発現の変化について検討した。Gleason score 3,4,5の各群でLSD1発現を免疫染色で定量化し比較したところ、悪性度の高い癌においてLSD1が高発現していることが確認された。Gleason scoreの高い癌は臨床においても治療抵抗性になりやすく、かつ転移をきたしやすいため、悪性度が高く癌性疼痛の原因になりやすい癌ほどLSD1の発現が高いことから、LSD1の癌性疼痛の標的としての可能性が示唆された。 (2)in vivoにおいて去勢がLSD1発現に与える影響の検討：本学において樹立した、ラット由来前立腺癌細胞株PCai1を用いて検討した。PCai1をCharcoal stripped mediumで長期間培養し、去勢抵抗性前立腺癌細胞株PCai1-CSを作成した。ウェスタンブロットを用いてPCai1とPCai1-CSにおけるLSD1発現を検討したところ、去勢によるLSD1発現の大きな変化は認めなかった。これは昨年度の臨床検体を用いた検討の結果とも一致しており、LSD1は去勢抵抗性の獲得の段階にかかわらず癌性疼痛の治療標的となりうる可能性が示唆された。 (3) 液体高速クロマトグラフ質量分析器（LC-MS）を用いたホルムアルデヒド検出の検討：前年度の蛍光を用いた検出方法よりさらに低濃度のホルムアルデヒドを高精度に検出する方法を確立するために、本学に導入されたLC-MSシステム（LC-MS8030 島津製作所）を用いて、ホルムアルデヒドの計測を試みた。除タンパクや誘導体化につき条件設定を行い、in vitroの条件でホルムアルデヒド試薬を用いてホルムアルデヒドが検出可能なことを確認できた。
  • 日本学術振興会：科学研究費助成事業 基盤研究(C)
    Date (from‐to) : 2019/04 -2022/03 
    Author : 畦元 将隆; 河合 憲康; 安藤 亮介; 惠谷 俊紀; 戸澤 啓一; 安井 孝周; 堤内 要; 内木 拓
     
    本研究の目的は温度感受性に抗癌剤を放出する磁性ナノ粒子(抗がん剤内包マグネタイト結合ナノホーン粒子(Thermo-SWNH))と交流磁場照射による磁場誘導組織内加温法の併用療法を浸潤性膀胱がんに対する治療として確立するための基礎研究である。臨床応用のためには解決するべく課題は1) Thermo-SWNHの最適化と安定供給体制 2)定量的スクリーニング系の構築（in vitro, in vivoでの腫瘍退縮効果確認） 3) 交流磁場発生装置の製造の3点である。私たちは磁場誘導組織内加温法の研究を長年おこなっており、前立腺がんを中心にその成果を報告してきた。そこでThermo-SWNHとの併用療法を浸潤性膀胱がんに対する新しい治療法として確立するための基礎研究として1). 抗がん剤内包マグネタイト結合ナノホーン粒子(Thermo-SWNH)の最適化と2).定量的スクリーニング系の構築（in vitro, in vivoでの腫瘍退縮効果確認）を主たる目的とし、交流磁場発生装置は、非臨床の段階のもではあるが、従来のものを用いることで改良点を模索する。 研究計画は初年度(2019年度)：抗がん剤内包マグネタイト結合ナノホーン粒子の作成であった。共同研究者との協力により以下の手順で作成した。①単層カーボンナノホーンに硝酸を加えて100℃で1時間硝酸化処理を行う。②硝酸化処理した単層カーボンナノホーンから鉄イオンを精製し開孔部を形成させる。③開孔部を形成した単層カーボンナノホーンに 80℃のアンモニアで処理し、マグネタイトナノ粒子を鞘の内部に取込ませる。 上記方法により2019年度にThermo-SWNHを作成することができた。
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2018/04 -2021/03 
    Author : Nakagawa Motoo
     
    Dual energy CT was performed on patients with bladder cancer, and monoenergetic images equivalent to 40 keV were reconstructed from the data of the images. These image data were compared with the image data of normal tube voltage 120 kVp imaging to examine whether there is a difference in the detection ability of bladder cancer. A comparison of the contrast effect of bladder cancer showed that the 40 keV images showed stronger contrast than the conventional 120 kVp images (P<0.01). The 40 keV images were also significantly more sensitive in detecting bladder cancer in subjective diagnostic imaging. These results were published in an English journal (Jpn J Radiol. 2022;40:177-183).
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2017/04 -2020/03 
    Author : Akita Hidetoshi
     
    LSD1, the first histone demethylase to be discovered, is a novel target in prostate cancer therapy. NCL1 and NCD38, novel selective cell-active inhibitors of LSD1, were discovered at our university. We analyzed the efficacy of LSD1 inhibitors in germ cell tumors. The WST assay revealed a reduction in the number of viable cells in a dose-dependent manner after NCL1 or NCD38 treatment. In western blotting, NCL1 or NCD38 treatment induced caspase-dependent apoptosis, while Oct4 and SOX2 expression was decreased. In flow cytometry analysis, NCL1 or NCD38 significantly induced apoptosis in a dose-dependent manner. Subcutaneous tumor volumes and serum AFP levels were significantly lower in mice treated with NCL1 or NCD38 than in controls. TUNEL analysis showed that NCL1 and NCD38 treatment induced apoptosis in NTERA2 subcutaneous tumors. Tissue array analysis showed that LSD1 expression in human seminoma specimens was significantly higher than that in noncancerous specimens.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2017/04 -2020/03 
    Author : NAGATA DAISUKE
     
    Recent report described that apparent diffusion coefficient (ADC) levels in magnetic resonance imaging (MRI) correlate the malignant levels in bladder carcinoma. However, those could not analyze including the prognosis. Therefore, the purpose of this study is to investigate the prognostic value of ADC levels in localized bladder cancer patient. From 2007 to 2012, total of eligible 141 patients who were performed TURB were enrolled.The median age was 71 years old. The T stage was 38 cases in pTa, 62 cases in pT1, and 41 cases in T2 or more, with 35 cases in low grade and 116 cases in high grade. The more T stage was worsened, ADC levels significantly decreased. Particular in pT1 cases, cases in low level of ADC group were significantly poor PFS compared with in high level group. Furthermore, multivariate analysis revealed that ADC levels was independent prognostic factor in pT1 patients. In pT1 bladder carcinoma patients, the ADC levels could be good prognostic biomarker.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2017/04 -2020/03 
    Author : Yamada Kenji
     
    Genomic instability is the hallmark of most human cancers, including bladder cancer. However, its role in tumor carcinogenesis is still poorly understood. In this study, to investigate chromosomal instabilities (CIN), bladder cancer mouse model was used. As measure of CIN, DNA copy number aberrations (CNA) were investigated. According to array comparative genomic hybridization (CGH) analysis to detect CNA throughout the genome, five chromosomes with high CIN were identified, and among the candidate genes present in these regions, ubiquinol-cytochrome c reductase binding protein (UQCRB) on chromosome13B3 was further characterized. In this study, our findings suggest that UQCRB is an indicator of bladder cancer, and may play important roles in carcinogenesis through the regulation of iNOS.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2017/04 -2020/03 
    Author : Naiki Taku
     
    Prostate cancer growth is androgen sensitive, therefore, the first-line therapy of prostate cancer is androgen deprivation therapy like castration. However, the therapeutic efficacy is limited and lead to castration resistant prostate cancer (CRPC). Previous study, we established the new CRPC model, and by analyzing them, we newly explored that oxidative stress induced mechanism was highly activated in CRPC. Therefore, in this study, we investigated the therapeutic efficacy of luteolin, which is one of natural flavonoids, in CRPC. As a result, luteolin suppressed CRPC growth both in vitro and in vivo, and the main mechanism of growth suppression was apoptosis regulated by ROS caused by the changes of molecular network. In conclusion, luteolin is promising chemotherapeutic agent for CRPC.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2016/04 -2019/03 
    Author : Ando Ryosuke
     
    The aim of this study was to examine the impact of insulin resistance on incident prostate cancer. A prospective cohort study was performed in 2,366 men aged 40-79 years who voluntarily received medical examinations between April 2007 and August 2011 and were free of any cancers. Follow-up data were obtained at 5 years after baseline. All participants measured serum insulin level at baseline. A homeostasis model assessment of insulin resistance was calculated to assess insulin resistance. Participants with diabetes or fasting glucose >140mg/dL at baseline were excluded. Of the participants, 60 men (2.5%) developed prostate cancer. Age and serum prostate specific antigen value at baseline were significantly higher in men with than in subjects without prostate cancer. We observed no statistically significant differences between insulin resistance and incident prostate cancer. In this study, it would be difficult to assess the impact of insulin resistance on prostate cancer.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2016/04 -2019/03 
    Author : ETANI TOSHIKI; TAKAHASHI satoru; SUZUKI takayoshi
     
    The CRPC cell lines, 22Rv1, PC3, and PCai1CS, were treated with NCL1, and LSD1 expression and cell viability were assessed. CRPC cells showed strong LSD1 expression, and cell viability was decreased by NCL1 in a dose-dependent manner. In western blotting and flow cytometry, NCL1 also dose-dependently induced caspase-dependent apoptosis. In addition, stimulation of autophagy was observed in NCL1-treated 22Rv1 cells by transmission electron microscopy and LysoTracker analysis. In ex vivo analysis, castrated nude mice were injected subcutaneously with PCai1 cells and intraperitoneally with NCL1. Tumor volume was found to be reduced with no adverse effects in NCL1-treated mice compared with controls. Finally, immunohistochemical analysis using consecutive human specimens in pre- and post-androgen deprivation therapy demonstrated that LSD1 expression levels in CRPC were very high, and identical to levels observed in previously examined prostate biopsy specimens.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)
    Date (from‐to) : 2016/04 -2018/03 
    Author : Iida Keitaro; Yasui Takahiro; Suzuki Takayoshi; Kawai Noriyasu; Ando Ryosuke; Naiki Taku; Etani Toshiki
     
    We investigated therapeutic potential of a novel histone lysine demethylase 1 (LSD1) inhibitor, NCL1, in bladder cancer. Bladder cancer cell lines were treated with NCL1, and LSD1 and cell viability were assessed. Bladder cancer cells showed strong LSD1 expression, and cell viability was decreased by NCL1. In addition, autophagy was induced by NCL1 treatment. Autophagy inhibitor, chloroquine, demonstrated synergic anti-tumor effect with NCL1. In TCGA database, LSD1 RNA expression in bladder cancer was significant higher than that in normal bladder tissues. We suggest that NCL1 and autophagy inhibitor is a potential therapeutic agent for bladder cancer.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2015/04 -2018/03 
    Author : Suzuki Shugo
     
    High mobility group box 2 (HMGB2), which belongs the HMG protein families, was up-regulated in prostate adenocarcinoma compared to normal epithelium. In this study, we investigated functions of HMGB2 for progression, androgen regulation and cell proliferation of hormone naive and castration resistant prostate cancer. In prostatectomy samples, HMGB2 expression was correlated with Gleason grading and tumor stage, but was not related with overall survival. Compared to hormone naive prostate cancer, HMGB2 expression in hormone-treated prostate cancer tended to be decreased, and was reverse correlated with therapeutic effect. In prostate cancer cell lines, HMGB2 regulated androgen receptor-mediated pathway in androgen dependent cell line, LNCaP. HMGB2 also regulated cell proliferation in both androgen dependent and independent cancer cell lines.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2015/04 -2018/03 
    Author : Kawai Noriyasu
     
    For the purpose of applying thermotherapy using magnetite and 8-MHz radio waves for the treatment of metastatic lesions of various solid cancers, we developed a method of injecting and stagnating magnetite into target organs using IVR technology. And we evaluated whether hyperthermia can treat these lesion with renal cancer model. Magnetite and Lipiodol blend were injected and the temperature of the same part was confirmed to rise with Thermotron RF-8. It was confirmed that it is possible to inject magnetite blend by ordinary IVR technology. At this time, hyperthermia treatment using IVR technology could not be performed, but by summarizing the data, the utility of this research towards the clinical application of magnetic microparticles into cancer metastasis via IVR technology is shown.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2015/04 -2018/03 
    Author : Takada Hideki; Kawai Noriyasu; Ando Ryosuke; Naiki Taku; Kobayashi Daichi
     
    As a new therapy that does not require surgical treatment, we developed thermotherapy (MCL Heat Therapy) using positively charged liposome-embedded magnetic nanoparticles (MCL) as a heating element, and prostate cancer We have reported the growth inhibitory effect of various cancers at the beginning. In that study, we found induction of strong antitumor immunity via MHC molecule of MCL Heat Therapy. In this study, we injected MCL bladder and irradiated with an alternating magnetic field to strengthen induction to Th1 and CTL and proved a significant tumor reduction effect. In addition, by administering anti-TGF-β antibody and anti-IL-6 antibody, induction of differentiation into Th-17, Treg was suppressed, induction to Th 1 was strengthened, and demonstrated stronger tumor reduction effect.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2014/04 -2017/03 
    Author : NAIKI Taku
     
    Prostate cancer growth is androgen sensitive, therefore, the first-line therapy of prostate cancer is androgen deprivation therapy like castration. However, the therapeutic efficacy is limited. Chemotherapy including taxane derivatives is next strategy in castration resistant prostate cancer (CRPC), however, the distribution of derivatives is various. Connexin 43 (Cx43) is a major gap junction (GJ) protein, and intracellular communication by using low molecular substances is normally performed through GJ. We previously established new CRPC animal models, and present study, cDNA microarray analyses revealed that Cx43 was suppressed in CRPC. Moreover, Cx43 regulates apoptotic signaling in castrated condition in new established Cx43 overexpressed prostate cancer cells. Therefore, GJ may play important roles in preventing castration resistant growth.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)
    Date (from‐to) : 2014/04 -2016/03 
    Author : Niwa Satomi; NAIKI Taku; SASAKI Shoichi; TAKAHASHI Satoru; OHYA Susumu
     
    Ca2+-activated K+ channels (KCa) are key molecules in cancer progression and are considered to be potential targets for cancer therapy. KCa2.2 was predominantly expressed in human prostate cancer (PCa) tissues and human PCa cell lines, LNCaP and VCaP, with higher expression levels of androgen receptor (AR). A Ca2+-activated K+ channel blocker, UCL1684 suppressed the cell proliferation through the inhibition of the store-operated Ca2+ entry (SOCE) in LNCaP cells. The anti-androgenic agents and the siRNA-mediated inhibition of AR expression downregulated the expression levels of KCa2.2 in LNCaP cells. Additionally, the expression levels of KCa2.2 was upregulated with the upregulation of AR transcripts under long-term, androgen-deficient condition, whereas it was downregulated under short-term condition. These results suggest that KCa2.2 might induce a possible candidate for novel treatment target of Castration-Resistant Prostate Cancer, CRPC.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2013/04 -2016/03 
    Author : Nagata Daisuke; KAWAI Noriyasu; KOHRI Kenjiro; ANDO Ryosuke; ETANI Toshiki; TOZAWA Keiichi
     
    We developed the new hyperthermic therapy (Magnetic induced intra cellular hyperthermia) which generate heat by magnetic nano particle: MNP). We connected an antibody of RANKL (nuclear factor kappa-B ligand) which became the key to exacerbation of prostate cancer bone metastases to MNP and gave it transvenously subsequently. And we studied in vitro and in vivo for the purpose of performing hyperthermia for bone invasion lesion after arriving of MNP at bone invasion lesion. It was confirmed that anti RANKL antibody-binding MNP significantly adhered to mouse osteoblasts MC3T3-E1 where RANKL was present in in vitro. Anti RANKL antibody-binding MNP were injected into rat prostate cancer bones invasion models transvenously. We were not able to examine confirming the effect of the hyperthermia.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2013/04 -2016/03 
    Author : Fukuta Katsuhiro; KAWAI Noriyasu; KOHRI Kenjiro; TOZAWA Keiichi; NAIKI Taku
     
    The background of the study is based on PEG has the feature as a chemotherapeuatic agent through the induction of multinucleated cell formation and apotosis induction in PC-3 prostate cancer cells. The aim of this study is to evaluate this effect of PEG for bladder cancer cells. However, in this study using the bladder cancer cell line, the expected results were not indicated. The bladder cancer was "urothelial cancer" histologically. The bladder cancer was thought to be different from prostate cancer which was "adenocarcinoma" histologically in a property. In the study using the human gastric cancer cells “NCI-N87” which were "adenocarcinoma", PEG suggested the effort of itself for “NCI-N87” cancer cells. We could not perform in vivo study in this study period. We are going to examine effects of the PEG by the cytological difference for "adenocarcinoma" "urothelial carcinoma" in future. By the results, we identify the carcinoma with responsibility.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
    Date (from‐to) : 2012/04 -2015/03 
    Author : KAWAI Noriyasu; KOBAYASHI Takeshi; KOHRI Kenjiro; TOZAWA Keiichi; SASAKI Shoichi; NAIKI Taku
     
    We developed several years ago new cancer thermotherapy “MCL Heat Therapy”, which is based on the particular character of the magnetite (Fe3O4). The character is generating heat by irradiation of alternative magnetic field. We performed basic research for the purpose of developing new therapy to treat both primary and metastatic lesion by which MCL Heat Therapy and cancer immunotherapy are fused. In vitro, we could not find the enhancement of tumor antigen from prostate cancer cell by heat therapy. However, in vitro, helper T cell and cytotoxic T cell were appeared in tumor tissue by MCL Heat Therapy. Under the acceptance of Institutional Review Bore of our university, new Heat Therapy with inductive heating machine RF-8 and local injection of MCL was performed for three patients. There were no adverse events.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)
    Date (from‐to) : 2012/04 -2014/03 
    Author : NAIKI Taku
     
    Prostate cancer generally acquires castration-resistant growth capacity with progression, resulting in resistance to anti-androgen therapy. Therefore, identification of genes that are regulated through this process may be important. We previously established a new castration-resistant prostate cancer (CRPC) metastatic model. We found that the glutathione peroxidase 2 (GPX2) gene was overexpressed in CRPC model, and we presented novel data showing that silencing of GPX2 by siRNA caused significant growth inhibition, and increased intracellular ROS in CRPC. Analyses of prostatectomy specimens demonstrated that GPX2 expression was significantly higher in residual cancer foci after hormone therapy than in hormone naive cancer foci. Moreover, patients with highly expressed GPX2 in biopsy specimen had significantly lower prostate-specific antigen recurrence-free survival and overall survival than those negative for GPX2. These findings suggest that GPX2 may be therapeutic target for CRPC.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)
    Date (from‐to) : 2010 -2011 
    Author : NAIKI Taku
     
    We established androgen-independent prostate cancer cell line from TRAP tumor, and named PCai1, and previously reported the orthotopic metastatic models, and tail vein injection model using PCai1 cells. We investigate the GST-P expression of PCai1 by RT-PCR and Western blot. In addition, using GST-P-siRNA, we investigated the relationship between the cell growth and Reactive Oxygen Species(ROS) in PCai1.PCai1 cells had higher GST-P expression in mRNA and protein levels in Charcoal Stripped-FBS medium than in normal medium. GST-P knocked down by siRNA resulted in significant decrease of the proliferation rate in vitro. On the contrary, DCFH assay revealed that ROS was induced by GST-P-siRNA treat. Tumors metastasized in the bone marrow after intravenous injection expressed high levels of GST-P, while metastatic lesions in the lung and lymph nodes failed to express GST-P as seen in the case of the orthotopic implantation. GST-P might have the important roles in the prostate cancer growth and metastasis by the restriction of ROS.

Other link

researchmap


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.